Ibarrola-Peña JC, Camacho-Mondragón CG, García R, De la Pena-Almaguer E, Cortes-Aguirre M

Language: English
References: 10
Page: 74-79
PDF size: 1775.65 Kb.

ABSTRACT

Introduction: premature ventricular complexes (PVCs) are linked to PVC-induced cardiomyopathy, functional deterioration, and poor quality of life (QOL). Presentation of case: a 54-year-old woman presented for evaluation with dyspnea and palpitations as her primary complaints. She was under follow-up for premature ventricular contractions (PVCs) and had been treated with oral antiarrhythmic therapy (bisoprolol). Despite improvement in chest pain, her response to treatment was poor. She experienced an increase in PVC frequency despite medication up-titration over a three-month follow-up period. She also reported a marked decline in functional capacity, characterized by exertional dyspnea, distress, and palpitations during moderate physical activity. Symptoms persisted at rest, with a significant negative impact on quality of life. As a result, she limited her physical activity to walking due to symptom burden and fear of palpitations. Conclusion: in selected cases, PVCs ablation can effectively relieve symptoms and enhance QOL.

REFERENCES

1. Attachaipanich T, Thiravetyan B, Tribuddharat N,Jaroonpipatkul S, Navaravong L. Premature ventricularcontraction-induced cardiomyopathy: contemporaryevidence from risk stratification, pathophysiology, andmanagement. J Clin Med. 2024; 13 (9): 2635.

2. Zeppenfeld K, Tfelt-Hansen J, De Riva M, Winkel BG,Behr ER, Blom NA et al. 2022 ESC Guidelines for themanagement of patients with ventricular arrhythmiasand the prevention of sudden cardiac death. Eur HeartJ. 2022; 43 (40): 3997-4126.

3. Panizo JG, Barra S, Mellor G, Heck P, AgarwalS. Premature ventricular complex-inducedcardiomyopathy. Arrhythmia Electrophysiol Rev. 2018;7 (2): 128-134.

4. Huizar JF, Ellenbogen KA, Tan AY, Kaszala K.Arrhythmia-induced cardiomyopathy: JACC stateof-the-art review. J Am Coll Cardiol. 2019; 73 (18):2328-2344.

5. Noheria A, Deshmukh A, Asirvatham SJ. Ablatingpremature ventricular complexes: justification,techniques, and outcomes. Methodist DebakeyCardiovasc J. 2015; 11 (2): 109-120.

6. Sorgente A, Farkowski MM, Iliodromitis K, GuerraJM, Jubele K, Chun JKR et al. Contemporary clinicalmanagement of monomorphic idiopathic prematureventricular contractions: results of the European HeartRhythm Association survey. Europace. 2022; 24 (6):1006-1014.

7. Voskoboinik A, Hadjis A, Alhede C, Im SI, Park H, MossJ et al. Predictors of adverse outcome in patients withfrequent premature ventricular complexes: The ABCVTrisk score. Heart Rhythm. 2020; 17 (7): 1066-1074.

8. Keegan R, Aguinaga L, Fenelon G, Uribe W, RodriguezDG, Scanavacca M et al. The first Latin Americancatheter ablation registry. Europace. 2015; 17 (5):794-800.

9. Mendoza-Herrera K, Pedroza-Tobías A, Hernández-Alcaraz C, Ávila-Burgos L, Aguilar-Salinas CA,Barquera S. Attributable burden and expenditure ofcardiovascular diseases and associated risk factorsin Mexico and other selected mega-countries. Int JEnviron Res Public Health. 2019; 16 (20): 4041.

10. Romero J, Patel K, Briceno D, Alviz I, Gabr M, Diaz JCet al. Endo-epicardial ablation vs endocardial ablationfor the management of ventricular tachycardia inarrhythmogenic right ventricular cardiomyopathy: asystematic review and meta-analysis. J CardiovascularElectrophysiol. 2020; 31 (8): 2022-2031.